ZCZahra Chavoshzadeh

Zahra Chavoshzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zahra Chavoshzadeh has a total of 485 co-authors. Here are the top co-authors by number of shared publications:

  • Mahnaz Jamee

    Human Immune Disorders Laboratory, Garvan Institute of Medical Research

    13 shared publications
  • Mehrnaz Mesdaghi

    Immunology and Allergy Department, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    11 shared publications
  • Nima Rezaei

    Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Tehran University of Medical Sciences Tehran Iran

    11 shared publications
  • Shahrzad Fallah

    Immunology and Allergy Department, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    10 shared publications
  • Mahboubeh Mansouri

    Immunology and Allergy Department, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    9 shared publications
  • Mazdak Fallahi

    Shahid Fahmideh Children Hospital, Iran University of Medical Sciences, Tehran, Iran

    9 shared publications

Latest Publications

  • Open Access

    Prevalence and Microbial Associations in Pediatric Chronic Granulomatous Disease: A Retrospective Case Series at Mofid and Masih Daneshvari Hospitals (2014 - 2019)

    by Bahar Shafaei, Narges Bazgir, Zahra Chavoshzadeh, Seyed Alireza Mahdaviani, Mehrnaz Mesdaghi, Samin Sharafian, Shahrzad Fallah, Fariba Shirvani

    Background: Chronic granulomatous disease (CGD) is an immune system disorder caused by NADPH oxidase dysfunction. This dysfunction reduces the ability of neutrophils and monocytes to combat infections, leading to recurrent infections with microorganisms such as Staphylococcus, Salmonella, and BCG. CGD is commonly diagnosed in children younger than 5 years and can cause a range of infectious and noninfectious complications. Objectives: This study aimed to describe the clinical and microbial profiles of infections in pediatric patients with CGD at two Iranian referral hospitals over a 5-year period. Methods: This retrospective consecutive case series included patients with CGD admitted to two hospitals between 2014 and 2019. All patients with confirmed CGD (nitroblue tetrazolium [NBT] < 5% or dihydrorhodamine [DHR] stimulation index < 10) were eligible. Six patients were excluded because of incomplete data or declined retrospective consent. Culture, polymerase chain reaction (PCR), and BacTec were used. Causative pathogens were defined by sterile-site isolation or clinical assessment. Fisher's exact test was used, and P < 0.05 was considered statistically significant. Results: The study included 30 patients with CGD who presented to the two hospitals between April 2014 and April 2019. Most patients were male. The mean age was 107.96 ± 59.08 months, and the median age at diagnosis was 60 months (interquartile range [IQR], 24 - 108). The mean number of hospital admissions was 1.89 (IQR, 1 - 2), and the median length of hospital stay was 25 days (IQR, 14 - 42). The most frequent clinical manifestations were pneumonia and lymphadenopathy. Streptococcus (33.3%) and Candida (30%) were the most common pathogens. No significant association was observed between the infecting microorganisms and growth status, number of admissions, immunoglobulin levels, or lesion type (Fisher's exact P > 0.05). Conclusions: Streptococcus and Candida predominated among Iranian pediatric patients with CGD, differing from global patterns. These findings support consideration of local microbial patterns when evaluating prophylactic strategies.

  • Human inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity

    by Iris Fagniez, Miyuki Tsumura, Antoine Guérin, Hassan Abolhassani, Samin Sharafian, Mehrnaz Mesdaghi, Toyoki Nishimura, Harsha Prasada Lashkari, Sadashiva Rao, Stephanie Richards, et al.

    We previously reported inherited retinoic acid–related orphan receptor γ T (RORγT) deficiency in seven patients from three ancestries (Chilean, Palestinian, and Saudi Arabian) with mycobacterial disease and chronic mucocutaneous candidiasis (CMC). We report here five additional patients from different ancestries (Afghan, Indian, Iranian, Japanese, and Sri Lankan), each homozygous for a new loss-of-function RORC variant. All but one patient—the exception receiving early prophylaxis—developed mycobacterial disease due to a near-complete depletion of innate-like adaptive T cells, including mucosa-associated invariant T and invariant natural killer T cells, low counts of adaptive TH1* and CD8+ T cells, and impaired Mycobacterium-induced IFN-γ production by the remaining cells of these subsets, NK cells, conventional CD4+ T, Vδ1, and Vδ2 γδT cells. Most patients also displayed CMC due to their low counts of TH17 and TH1* cells. One patient died from disseminated Bacille Calmette-Guérin vaccine infection, but, unexpectedly, all the other patients are still alive and clinically stable at ages of 2 to 20 years. RORγT is essential for protective immunity against mycobacteria and Candida in humans.

  • Open Access

    Humans homozygous for rare or common hypomorphic IL23R variants are prone to tuberculosis

    by Diana Olguín Calderón, Laura E. Kilpatrick, Clément Conil, Quentin Philippot, Masato Ogishi, Joseph Vellutini, Ji Eun Han, Narelle Keating, Hailun Li, Geetha Rao, et al.

    Homozygosity for rare loss-of-function IL23R variants abolishes IL-23–dependent IFN-γ production by lymphocytes, including NK and innate-like T cells, thereby underlying clinical disease due to weakly virulent mycobacterial species. We report selective enrichment in homozygosity for four hypomorphic IL23R variants in our cohort of patients with tuberculosis. Three of these IL23R alleles are rare (G300V, G149R, and L372F), with a minor allele frequency (MAF) under 1%, but the fourth (R381Q) is surprisingly common, with an MAF as high as 10.2% in certain populations. The other 15 missense alleles found in the homozygous state in public databases are isomorphic. The four hypomorphic IL-23R variants identified dimerize with IL-12Rβ1 and bind IL-23. However, their function is impaired by low levels of cell surface expression (R381Q, G300V) and/or as a consequence of conformational changes altering agonist efficacy. IFN-γ production in response to IL-23 is impaired in innate-like T cells and NK cells. These data suggest that recessive partial IL-23R deficiency, whether due to rare or common variants, confers a predisposition to tuberculosis while preserving immunity to less virulent mycobacteria.


  • Open Access

    BCG arthritis in a patient with Severe Combined Immunodeficiency Disorder (SCID): a case report

    by Shabnam Eskandarzadeh, Zahra Chavoshzadeh, Mohammad Assadi Fanid, Babollah Ghasemi, Amirreza Jabbaripour Sarmadian

    Background: Severe combined immunodeficiency (SCID) is a rare group of primary immunodeficiency disorders characterized by profound defects primarily in T cells and, in certain subtypes, in B and NK cells as well. These immune deficiencies predispose affected patients to life-threatening infections and complicate their clinical management. Since the BCG vaccine is routinely administered to neonates in most countries, undiagnosed SCID patients face a significant risk of developing severe localized or disseminated BCG-related complications. Therefore, it should be taken into account in suspicious populations. Case presentation: The patient was a 16-month-old Iranian male with JAK3 gene mutation-associated SCID who presented with progressive left elbow swelling, pain, and restricted mobility over 10 days. Physical examination revealed tachycardia, fever, marked swelling and tenderness with severely restricted range of motion, and a firm, fixed, warm palpable mass. Soft tissue ultrasound demonstrated moderate joint effusion with synovial thickening, multiple irregular hypoechoic areas, and increased Doppler vascularity consistent with chronic monoarthritis and periarticular masses of probable bacterial origin. Given the lack of response to empirical therapy and conservative management, surgical excision was performed. Histopathological examination revealed neoplastic spindle cell proliferation with hyperchromatic nuclei, epithelioid macrophages, mixed inflammatory infiltrate, and numerous acid-fast bacilli both intracellularly and extracellularly. To reliably distinguish BCG from other members of the Mycobacterium tuberculosis complex, molecular analysis was performed, which demonstrated deletion of the RD1 region, confirming BCG arthritis. Following surgery and antimycobacterial therapy, the patient demonstrated marked clinical improvement, particularly in elbow range of motion, and was discharged after completing intravenous antibiotics and achieving clinical stabilization. Conclusions: This case underscores the critical need for revised immunization policies in TB-endemic countries, implementation of systematic neonatal primary immunodeficiency screening programs such as TREC screening, and enhanced healthcare provider awareness regarding the potentially catastrophic consequences of BCG vaccination in immunocompromised populations.


  • Open Access

    Demographic, clinical, and immunological features in combined immunodeficiency patients: a comparative analysis of those with and without pulmonary manifestations – a multicenter study from Iran

    by Ghamartaj Khanbabaee, Matin Pourghasem, Mahnaz Jamee, Seyed Ahmad Tabatabaii, Mitra Khalili, Samin Sharafian, Mehrnaz Mesdaghi, Mahnaz Sadeghi-Shabestari, Armin Shirvani, Saeid Sadr, et al.

    Background: Combined immunodeficiency (CID) involves profound defects in B and T lymphocyte development and function. This study examined clinical and immunological phenotypes of CID patients with and without pulmonary manifestations. Methods: This retrospective multicenter study included 53 CID patients diagnosed between 2009 and 2022 with available thoracic computed tomography scans. Patients were categorized based on pulmonary manifestations presence. Demographic, clinical, and laboratory characteristics were compared using conservative statistical thresholds ( P < 0.01). All laboratory parameters were interpreted using age-adjusted pediatric reference ranges. Results: Among 53 patients (56.6% male), 43 had pulmonary abnormalities on HRCT. Common clinical features included skin lesions (43.4%), failure to thrive (34%), and autoimmunity (32.1%). HRCT revealed pneumonia (28.3%), bronchiectasis (18.9%), interstitial lung disease with BOOP-like pattern (3.8%), and other findings. Using age-adjusted pediatric reference ranges, profound immunological defects were confirmed: absolute lymphocyte count below the 5th percentile in 92% (49/53), CD3 + T cells below the 5th percentile in 94% (47/50 tested), CD4 + T cells below the 5th percentile in 96% (51/53), CD19 + B cells below the 5th percentile in 94% (50/53), and hypogammaglobulinaemia (IgG below the 5th percentile) in 98% (52/53). Patients with abnormal HRCT had significantly lower CD4 + T-cell counts (178 vs. 498 cells/µL; P = 0.008) and CD19 + B-cell counts (42 vs. 189 cells/µL; P = 0.009). Bronchoscopy identified Aspergillus fumigatus, Streptococcus pneumoniae, and multidrug-resistantAcinetobacter baumannii. Deceased patients showed significantly lower baseline platelets (183,000 vs. 266,000 cells/µL; P = 0.009), IgG (380 vs. 720 mg/dL; P = 0.007), and IgE (0.8 vs. 12 IU/mL; P = 0.008). Conclusion: Pulmonary manifestations affect 81.1% of Iranian CID patients. Low baseline platelets, IgG, and IgE constitute a robust prognostic triad for mortality ( P = 0.009, P = 0.007, P = 0.008 respectively). Application of age-adjusted reference ranges revealed profound immunological defects. Systematic HRCT surveillance using low-dose protocols and distinguishing infectious sequelae from immune-mediated lung disease guides targeted management in resource-limited settings.

  • Open Access

    Complete and partial forms of X-linked MCTS1 deficiency in patients with mycobacterial disease

    by Qinhua Zhou, Ivan Bagarić, Fabian Komma, Chandhana Prakash, Hassan Abolhassani, Zahra Chavoshzadeh, Lulu Tsao, Taja Vatovec, Camille Soudée, Jérémie Rosain, et al.

    X-linked recessive (XR) complete MCTS1 deficiency underlies Mendelian susceptibility to mycobacterial disease (MSMD) in patients with bacille Calmette-Guérin (BCG) disease. We investigated the genotypic and phenotypic landscape of four new unrelated families from four distinct countries. Three patients had adverse reactions to the BCG vaccine, whereas another patient was not vaccinated with BCG and had an infection with Mycobacterium abscessus at 16 years of age. Whole-exome sequencing of the probands revealed hemizygosity for rare germline MCTS1 variants. In addition to a previously reported loss-of-expression (LOE) and loss-of-function (LOF) variant, we identified three new MCTS1 variants. The p.L170* and E60Kfs5* variants are LOF, whereas p.W175* is hypomorphic when overexpressed. Thus, we report four new MSMD patients with complete or partial forms of XR MCTS1 deficiency, including three patients with newly discovered genotypes. A diagnosis of partial or complete XR MCTS1 deficiency should be considered in boys and men with MSMD displaying mycobacterial infection.


  • Open Access

    A novel gross deletion in SMARCAL1 impairs DNA replication fork regression, leading to severe Schimke immuno-osseous dysplasia; a literature review and an integrated study of clinical, genetic, and protein-protein interaction analysis

    by Mohammad Saberi, Morteza Talebi, Ali Ghorbani, Azadeh Reshadmanesh, Samin Sharafian, Zahra Chavoshzadeh, Masumeh Mohkam, Arefeh Zahmatkesh, Paniz Pourpashang

    Schimke immuno-osseous dysplasia (SIOD) is an exceptionally rare autosomal recessive disorder that affects multiple organ systems, most notably the skeletal system, kidneys, and immune system. The clinical manifestations of SIOD include growth retardation, skeletal deformities, progressive proteinuria, and immunodeficiency. Severe cases may progress to nephrotic syndrome and cerebral infarctions. The disorder is primarily attributed to biallelic mutations in the SMARCAL1 gene, which leads to the early onset of symptoms and often results in premature mortality. In this study, we identified a novel gross deletion encompassing exons 5 and 6 of the SMARCAL1 gene. This deletion leads to a partial loss of the HARP1 and HARP2 domains and the generation of a novel HARP domain that is structurally similar to both HARP1 and HARP2, while retaining conserved amino acids. Our AlphaFold 3D modeling indicated that the truncated SMARCAL1 protein is identical to the wild-type SMARCAL1, except for the absence of HARP1 domain, and resembles invertebrate SMARCAL1, which naturally possesses only one HARP domain. Previous studies have demonstrated that human SMARCAL1 lacking the HARP1 domain retains normal helicase, ATPase, and DNA-binding activities. Additionally, invertebrate SMARCAL1, which also lacks the HARP1 domain, fails to effectively regress DNA replication forks. This suggests that the identified gross deletion may contribute to SIOD pathogenesis by impairing DNA replication fork regression and genomic instability

  • Measuring Dedicator of Cytokinesis 8 (DOCK8) Expression as a Flow Cytometry Biomarker for DOCK8 Deficiency Detection

    by Maryam Moradi, Mahsa Yousefpour Marzbali, Nazanin Nazari, Zahra Chavoshzadeh, Seyed Alireza Mahdaviani, Mahnaz Sadeghi-Shabestari, Nima Rezaei

    The autosomal recessive form of hyperimmunoglobulin E syndrome (AR-HIES), caused by mutations in the DOCK8 (Dedicator of Cytokinesis 8) gene, presents a wide range of clinical manifestations and phenotypically overlaps with several types of combined immunodeficiency disorders characterized by elevated serum IgE levels. Due to the high rates of morbidity and mortality, as well as the potential curability through hematopoietic stem cell transplantation (HSCT), early and accurate differential diagnosis of this syndrome is crucial for optimal management and improved prognosis. Flow cytometry tests can be beneficial for early diagnosis of many inborn errors of immunity (IEIs), including this syndrome. This study, conducted for the first time on Iranian patients, investigated the expression of the DOCK8 protein. DOCK8 expression was assessed by flow cytometry in 14 patients (6 males and 8 females) with a clinical diagnosis of DOCK8 deficiency. The diagnosis was ultimately confirmed through genetic testing. The results showed that DOCK8 expression in patients was significantly lower compared to the healthy control group. Flow cytometric evaluation of DOCK8 protein expression offers a rapid and efficient diagnostic method with a sensitive detection range suitable for many cases. This approach can facilitate the diagnosis of DOCK8 deficiency, thereby enabling timely and effective disease management.

  • A Report on the Clinical Efficacy of Rituximab Administration in Patients with Inborn Errors of Immunity and Autoimmune/Autoinflammatory Manifestations

    by Samin Sharafian, Mahya Mohammadi, Samin Alavi, Mehrnaz Mesdaghi, Reza Shiari, Bibi Shahin Shamsian, Peyman Eshghi, Hedieh Haji Khodaverdi Khani, Hassan Abolghasemi, Abdollah Karimi, et al.

    It can sometimes be very difficult to control the manifestations of autoimmunity and lymphoproliferation in patients with primary immunodeficiency diseases, and there is no adequate response to first-line treatments. Rituximab (RTX), as a second-line treatment, is efficacious and well-tolerated for the management of these clinical manifestations. This retrospective study was conducted to analyze the clinical, immunological, and geneticfindings together with the response rate to RTX therapy in subjects with inborn errors of immunity (IEI) and autoimmune or autoinflammatory manifestations. In this study, 23 individuals with IEI and autoimmune or lymphoproliferation manifestations who received RTX between April 2008 and 2021 were evaluated. Fifteen out of the 23 patients were female. The median age of cases was 12 years. The moderate and severe adverse reactions, including fever, diarrhea, and anaphylaxis shock, were manifested during RTX infusion in 5 patients. In total, 86.9% of patients responded to rituximab (complete response: n=14, partial response: n=6) while three failed to respond. The median response time to RTX treatment was 50 days. All patients were given monthly intravenous immunoglobulin (IVIG) therapy. Pneumonia and candidiasis occurred in one patient a week after receiving the second injection of RTX. Eight patients expired during follow-up. In conclusion, the response rate of RTX could be improved through administering monthly IVIG for hypogammaglobulinemia treatment following RTX infusion. Early use of rituximab leads to a better response rate in comparison with late use of rituximab in multitreated refractory patients. The efficient cumulative dose of rituximab remains undefined.

  • A novel variant in the STIM1 gene leading to combined immunodeficiency and congenital myopathy

    by Amirreza Taherkhani, Mahmood Gorjizad, Farzad Ahmadabadi, Mohammad Saberi, Samin Sharafian, Mehrnaz Mesdaghi, Samin Alavi, Ali Akbar Sayari, Samaneh Abdolahzadeh, Sahar Seraj, et al.

    Stromal interaction molecule 1 (STIM1) is a transmembrane protein located in the endoplasmic and sarcoplasmic reticulum, where it plays a crucial role in activating calcium release-activated calcium (CRAC) channels. It functions as a calcium (Ca2⁺) sensor within the endoplasmic reticulum (ER), triggering CRAC channel opening and allowing calcium entry—mechanisms essential for maintaining intracellular calcium homeostasis. Mutations in the STIM1 gene that impair calcium signaling can disrupt both T cell and muscle cell function, leading to combined immunodeficiency and congenital myopathy. Here, we describe a 9-year-old boy with these clinical features, who was found to carry a previously undescribed mutation in the STIM1 gene. The patient presented with recurrent pneumonia, blood-streaked diarrhea, eczema, muscle weakness, and failure to thrive. Whole exome sequencing identified a novel homozygous missense variant in STIM1 (c.584T > C | p.Leu195Pro), considered likely pathogenic. This classification was supported by high Combined Annotation Dependent Depletion (CADD) and Rare Exome Variant Ensemble Learner (REVEL) scores of 29.8 and 0.89, respectively. Homozygosity of the mutation was confirmed using PCR-Sanger sequencing. This case highlights a novel homozygous STIM1 variant in a child with combined immunodeficiency and congenital myopathy. The clinical presentation is consistent with previously reported phenotypes associated with STIM1 deficiency.